Sort   by:  
 Page size 
TranscriptomicsHuman BRAF-V600E melanoma cell lines drug sensitive vs drug resistant
aCGH of human melanoma cell lines comparing parental (drug sensitve) vs isogenic drug resistant-derived subline Two condition experiment: two BRAF-V600E mutant cell lines (drug sensitive - parental baseline) vs two derived sublines after chronic exposure to the MEK inhibitor trametinib (drug resista...
ORGANISM(S): Homo sapiens 
2014-04-21 | E-GEOD-49430 | biostudies-arrayexpress
TranscriptomicsComparison between HuT78 parental and romidpepsin-selected cell lines
Gene expression values were determined for HuT78 parental cells and cells selected with romidpesin in the presence of P-glycoprotein inhibitors. HuT78 DpVp35 cells are maintained in 35 ng/ml romidepsin with 2.5 µg/ml verapamil and HuT78 DpP100 cells are maintained in 100 ng/ml romidepsin with 1 µM v...
ORGANISM(S): Homo sapiens 
2013-03-12 | E-GEOD-45018 | biostudies-arrayexpress
ProteomicsMulti-omics characterization of MEK inhibitor resistant pancreatic cancer based on a genetically engineered mouse model-derived in vitro system
Tumor heterogeneity and therapy resistance are hallmarks of pancreatic ductal adenocarcinoma (PDAC). Emerging evidence supports treatment-induced resistance to be a multifactorial process mediated by cellular plasticity involving epigenetic regulation. Here, we used a multi-omics approach to analyze...
ORGANISM(S): Mus musculus (Mouse) 
2024-01-26 | PXD018093 | Pride
Mouse model Pdac Mek inhibitor resistant Lc-ms/ms 
TranscriptomicsExpression data from BRAF-mutant melanoma cell lines
Melanoma cell lines were assessed for differences in gene expression patterns between the lines sensitive and resistant to BRAF and MEK inhibitor drugs. 22 BRAF-mutant melanoma cell lines were assessed for response to BRAF and MEK inhibitors in a 3 day drug treatment dose response assay. Based on t...
ORGANISM(S): Homo sapiens 
2015-08-26 | E-GEOD-45558 | biostudies-arrayexpress
TranscriptomicsComparison of the genetic extinction of NRAS to pharmacological MEK inhibition in an inducible mouse model of melanoma
Since direct pharmacological inhibition of RAS has thus far been unsuccessful, we explored system biology approaches to identify synergistic drug combination(s) that can mimic direct RAS inhibition. Leveraging an inducible mouse model of NRAS-mutant melanoma, we compare pharmacological MEK inhibitio...
ORGANISM(S): Mus musculus 
2012-08-08 | E-GEOD-39984 | biostudies-arrayexpress
TranscriptomicsSuppression of IFN-induced transcription underlies IFN defects generated by activated Ras/MEK in human cancer cells
Certain oncolytic viruses exploit activated Ras signalling in order to replicate in cancer cells. Constitutive activation of the Ras/MEK pathway is known to suppress the effectiveness of the interferon (IFN) antiviral response, which may contribute to Ras-dependent viral oncolysis. Here, we identifi...
ORGANISM(S): Homo sapiens 
2012-08-02 | E-GEOD-31019 | biostudies-arrayexpress
TranscriptomicsSingle cell RNA-seq of pancreatic mouse tumors upon treatment
KRAS-mutant pancreatic ductal adenocarcinoma (PDAC) is highly immunosuppressive and resistant to targeted therapies, immune checkpoint blockade and engineered T cells. In this study, we performed a systematic high throughput combinatorial drug screen and identified a synergistic interaction between ...
ORGANISM(S): Mus musculus 
2021-11-13 | E-MTAB-9954 | biostudies-arrayexpress
ProteomicsSILAC-based quantification reveals modulation of the immunopeptidome in BRAF and MEK inhibitor-treated and resistant tumor cells
The immunopeptidome is constantly monitored by T cells to detect foreign or aberrant HLA peptides. It is highly dynamic and reflects the current cellular state, enabling the immune system to recognize abnormal cellular conditions, such as those present in cancer cells. To precisely determine how cha...
ORGANISM(S): Homo sapiens (Human) 
2025-05-07 | PXD054097 | Pride
Kinase inhibitor resistance Immunopeptidomics Cancer Mass-spectrometry Cryptic peptides Mapk signaling Melanoma Lc-ms/ms 
TranscriptomicsSynergistic anti-tumor activity by association of MEK and PI3K/mTOR blockade with TRAIL in human melanoma
Combining direct anti-tumor effects with targeting of tumor microenvironment is an attractive strategy that may lead to more effective therapies for advanced melanoma. Here, we tested whether association of TRAIL with co-targeting of MEK and PI3K/mTOR, or with MEK blockade, could have synergistic a...
ORGANISM(S): Homo sapiens 
2014-10-08 | E-GEOD-55050 | biostudies-arrayexpress
GenomicsBRAF and MEK resistant cell line clones
The Sanger Institute has the largest collection of genetically-characterised cancer cell lines world-wide (we have collected >1000 human cancer cell lines which are being screened against >400 cancer therapeutics (http://www.sanger.ac.uk/genetics/CGP/translation). These lines have been characterized...
EGAS00001000172 | EGA
Sort   by:  
 Page size